For patients who struggle with reflux on either medication alone, the GLP-Squared combination (dual compound of semaglutide and tirzepatide, at $289/mo month-to-month, or from $249/mo on the 6-month plan for injection) may offer a different balance of GLP-1 and GIP receptor activation that some patients tolerate better
For most people, this happens gradually, putting on around 0.5kg per year during their 40s and 50s
During the first weeks, you can expect: Reduced appetite Steady improvement in cravings Some temporary digestive effects that typically resolve Gradual progress as your dose increases With consistent use, healthy eating, and expert medical guidance, many patients experience noticeable and lasting results beginning within the first month
Parkinsons disease, characterized by dopaminergic neuronal loss in the substantia nigra leading to motor and non-motor symptoms, has also been linked to insulin resistance and impaired cerebral insulin signaling.128 GLP-1RAs and GLP-1/GIP dual-receptor agonists have demonstrated the capacity to enhance insulin sensitivity and exert antioxidant and anti-inflammatory effects in the brain.129 Preclinical studies in various PD animal models indicate that GLP-1RAs such as liraglutide, semaglutide, and lixisenatide promote dopamine synthesis and elevate striatal dopamine levels, thereby conferring neuroprotection to dopaminergic neurons.130132 The dual agonist telpor similarly exhibits neuroprotective effects by improving energy metabolism and inhibiting inflammatory pathways in PD models.126 Clinical trials have assessed the efficacy and safety of GLP-1RAs in PD patients with PD
doi: 10.1042/BCJ20160616 13 YoshikawaK
